subscribeSubscribe
price-trendAsk Us
BMS` Biologic Emplicti (Elotuzumab) Receives Approval in the U.S.

BMS` Biologic Emplicti (Elotuzumab) Receives Approval in the U.S.
FDA
22 Mar 2022
Share Share
Indapta Therapeutics Announces New Preclinical Data for Proprietary G-NK Cells

Indapta Therapeutics Announces New Preclinical Data for Proprietary G-NK Cells
BUSINESSWIRE
10 Aug 2021
Share Share
Bristol Myers Empliciti (Elotuzumab) Receives Supplemental Approval in US

Bristol Myers Empliciti (Elotuzumab) Receives Supplemental Approval in US
FDA
31 Oct 2019
Share Share
Bristol-Myers, AbbVie`s multiple myeloma drug wins second EU nod as part of triple regimen

Bristol-Myers, AbbVie`s multiple myeloma drug wins second EU nod as part of triple regimen
Natalie Grover ENDPTS
29 Aug 2019
Share Share
Empliciti combo bags EU approval for multiple myeloma

Empliciti combo bags EU approval for multiple myeloma
Anna Smith PHARMA TIMES
29 Aug 2019
Share Share
EC OKs expanded label for Bristol-Myers` Empliciti

EC OKs expanded label for Bristol-Myers` Empliciti
Douglas W. House SEEKINGALPHA
27 Aug 2019
Share Share
J&J eyes Darzalex convenience, safety boost with subcutaneous win

J&J eyes Darzalex convenience, safety boost with subcutaneous win
Carly Helfand FIERCE PHARMA
05 Jun 2019
Share Share
BMY`s to Present New Data on 20 Types Cancer from Across its Oncology Portfolio

BMY`s to Present New Data on 20 Types Cancer from Across its Oncology Portfolio
PRESS RELEASE
17 May 2019
Share Share
Bristol Myers Squibb` Biological Empliciti(Elotuzumab) Receives Supplemental Approval in US

Bristol Myers Squibb` Biological Empliciti(Elotuzumab) Receives Supplemental Approval in US
FDA
15 Nov 2018
Share Share
US approves new use for BMS’ Empliciti

US approves new use for BMS’ Empliciti
Selina McKee PHARMA TIMES
08 Nov 2018
Share Share